Association Between Incomplete Neoadjuvant Radiotherapy and Survival for Patients With Locally Advanced Rectal Cancer
Kyle FreischlagZhifei SunMohamed A. AdamJina KimManisha PaltaBrian G. CzitoJohn MigalyChristopher R. Mantyh
Abstract
Achieving a target radiation dose of 45.0 to 50.4 Gy is associated with a survival benefit in patients with locally advanced rectal cancer. Aligning all aspects of multimodal oncology care may increase the probability of completing neoadjuvant therapy.
Metrics
Citation History
Topics
Related Documents
Association between neoadjuvant chemoradiation and survival for patients with locally advanced rectal cancer
Zhifei SunMohamed A. AdamJ. KimMegan C. TurnerDeborah A. FisherKingshuk Roy ChoudhuryBrian G. CzitoJohn MigalyChristopher R. Mantyh
Neoadjuvant Capecitabine Combined with Standard Radiotherapy in Patients with Locally Advanced Rectal Cancer
Juergen DunstJürgen DebusVolker RudatJoern WulfWilfried BudachTobias HoelscherThomas S. ReeseStephan MoseClaus RöedelHelmut ZuehlkeAxel Hinke
Neoadjuvant chemotherapy without radiotherapy for patients with locally advanced rectal cancer. Oncologic outcomes
Javier A. CienfuegosJavier RodríguezJorge BaixauliA. Chopitea OrtegaA. García-ConsuegraMarta AbengózarCarles JusticiaJosé Luis Hernández Lizoain
Prognostic factors in locally advanced rectal cancer treated with neoadjuvant radiotherapy
Samah Al AlawiMohammed Al Hosni
Dose escalation in neoadjuvant radiotherapy of locally advanced rectal cancer
Ivanov, OliveraRakin, MilijanaAničić, NatašaBojović, MarkoLičina, JelenaPetrović, Borislava